193 related articles for article (PubMed ID: 24998602)
1. Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors.
Putey A; Fournet G; Lozach O; Perrin L; Meijer L; Joseph B
Eur J Med Chem; 2014 Aug; 83():617-29. PubMed ID: 24998602
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.
Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM
Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682
[TBL] [Abstract][Full Text] [Related]
3. Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1.
Aubry C; Wilson AJ; Emmerson D; Murphy E; Chan YY; Dickens MP; García MD; Jenkins PR; Mahale S; Chaudhuri B
Bioorg Med Chem; 2009 Aug; 17(16):6073-84. PubMed ID: 19632122
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents.
Kassis P; Brzeszcz J; Bénéteau V; Lozach O; Meijer L; Le Guével R; Guillouzo C; Lewiński K; Bourg S; Colliandre L; Routier S; Mérour JY
Eur J Med Chem; 2011 Nov; 46(11):5416-34. PubMed ID: 21944287
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.
Zhu G; Conner SE; Zhou X; Chan HK; Shih C; Engler TA; Al-Awar RS; Brooks HB; Watkins SA; Spencer CD; Schultz RM; Dempsey JA; Considine EL; Patel BR; Ogg CA; Vasudevan V; Lytle ML
Bioorg Med Chem Lett; 2004 Jun; 14(12):3057-61. PubMed ID: 15149644
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of novel 5-substituted indirubins as protein kinases inhibitors.
Beauchard A; Ferandin Y; Frère S; Lozach O; Blairvacq M; Meijer L; Thiéry V; Besson T
Bioorg Med Chem; 2006 Sep; 14(18):6434-43. PubMed ID: 16759872
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor.
Opoku-Temeng C; Dayal N; Hernandez DE; Naganna N; Sintim HO
Chem Commun (Camb); 2018 May; 54(36):4521-4524. PubMed ID: 29629444
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H
Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601
[TBL] [Abstract][Full Text] [Related]
11. 1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
Al-awar RS; Ray JE; Hecker KA; Huang J; Waid PP; Shih C; Brooks HB; Spencer CD; Watkins SA; Patel BR; Stamm NB; Ogg CA; Schultz RM; Considine EL; Faul MM; Sullivan KA; Kolis SP; Grutsch JL; Joseph S
Bioorg Med Chem Lett; 2004 Jun; 14(12):3217-20. PubMed ID: 15149678
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L
Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones.
Kunick C; Lauenroth K; Wieking K; Xie X; Schultz C; Gussio R; Zaharevitz D; Leost M; Meijer L; Weber A; Jørgensen FS; Lemcke T
J Med Chem; 2004 Jan; 47(1):22-36. PubMed ID: 14695817
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors.
Arfeen M; Bhagat S; Patel R; Prasad S; Roy I; Chakraborti AK; Bharatam PV
Eur J Med Chem; 2016 Oct; 121():727-736. PubMed ID: 27423119
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of new dipyrrolo- and furopyrrolopyrazinones related to tripentones and their biological evaluation as potential kinases (CDKs1-5, GSK-3) inhibitors.
Rochais C; Duc NV; Lescot E; Sopkova-de Oliveira Santos J; Bureau R; Meijer L; Dallemagne P; Rault S
Eur J Med Chem; 2009 Feb; 44(2):708-16. PubMed ID: 18586356
[TBL] [Abstract][Full Text] [Related]
17. Concise synthesis and CDK/GSK inhibitory activity of the missing 9-azapaullones.
Power DP; Lozach O; Meijer L; Grayson DH; Connon SJ
Bioorg Med Chem Lett; 2010 Aug; 20(16):4940-4. PubMed ID: 20621478
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, Biological, and Computational Evaluation of Novel 1,3,5-Substituted Indolin-2-one Derivatives as Inhibitors of Src Tyrosine Kinase.
Kilic-Kurt Z; Bakar F; Ölgen S
Arch Pharm (Weinheim); 2015 Oct; 348(10):715-29. PubMed ID: 26260414
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
